<p>阿尔法泰克（NASDAQ:ATEC - 获取免费报告）在周四发布给客户和投资者的研究报告中，投资分析师将其目标价格从 28.00 美元下调至 14.00 美元，彭博社报道。该公司目前对这家医疗技术公司的股票给予 “增持” 评级。摩根士丹利的目标价格暗示该公司股价有 83.37% 的潜在上涨空间。</p>
<p>其他几位股票分析师最近也对该公司发布了报告。Canaccord Genuity Group 将阿尔法泰克的目标价格从 25.00 美元下调至 23.00 美元，并在周三的研究报告中给予该公司 “买入” 评级。HC Wainwright 在周四的研究报告中重申了 “买入” 评级，并设定了 24.00 美元的目标价格。Weiss Ratings 在 3 月 27 日的研究报告中重申了阿尔法泰克的 “卖出（e+）” 评级。Wall Street Zen 在 1 月 31 日的研究报告中将阿尔法泰克的评级从 “持有” 上调至 “买入”。最后，巴克莱在周四的研究报告中重申了 “增持” 评级，并将目标价格设定为 24.00 美元（低于 27.00 美元）。十位投资分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，平均目标价格为 18.58 美元。</p>
<p><strong>查看我们关于 ATEC 的最新报告</strong></p>
<h2>阿尔法泰克股票上涨 9.2%</h2>
<p>在周四的午盘交易中，NASDAQ:ATEC 上涨 0.65 美元，达到 7.64 美元。该公司的交易量为 5,070,841 股，而其平均交易量为 3,239,526 股。该公司的 50 日简单移动平均为 11.60 美元，200 日简单移动平均为 15.90 美元。公司的流动比率为 2.06，速动比率为 1.28，债务与股本比率为 40.35。阿尔法泰克的 1 年最低价为 6.85 美元，1 年最高价为 23.29 美元。该公司的市值为 11.7 亿美元，市盈率为-9.34，贝塔值为 0.96。</p>
<p>阿尔法泰克（NASDAQ:ATEC - 获取免费报告）最后一次公布财报是在 5 月 5 日，医疗技术公司报告每股收益（EPS）为-0.22 美元，低于分析师一致预期的-0.01 美元，差距为-0.21 美元。阿尔法泰克的股本回报率为-788.36%，净利润率为-15.93%。该公司在本季度的收入为 1.9211 亿美元，而分析师预期为 1.9751 亿美元。在去年同期，该公司每股收益为-0.35 美元。与去年同期相比，该公司的收入增长了 13.6%。股票分析师预测阿尔法泰克在本财年的每股收益将为-0.28 美元。</p>
<h2>阿尔法泰克的内部买卖</h2>
<p>在相关消息中，首席运营官 Scott Lish 在 3 月 13 日的交易中出售了 260,535 股公司的股票。股票以平均价格 12.30 美元出售，总价值为 3,204,580.50 美元。出售完成后，首席运营官直接持有该公司 815,704 股股票，价值约为 10,033,159.20 美元。这代表其持股比例减少了 24.21%。该交易在向 SEC 提交的文件中披露，文件可通过此链接访问。此外，法律顾问 Tyson Eliot Marshall 在 3 月 5 日的交易中出售了 88,835 股公司的股票。股票以平均价格 12.49 美元出售，总交易额为 1,109,549.15 美元。出售完成后，法律顾问持有 559,459 股公司的股票，价值为 6,987,642.91 美元。这代表其持股比例减少了 13.70%。该交易的披露信息可在 SEC 文件中找到。在过去三个月中，内部人士共出售了 629,189 股公司股票，价值为 7,801,589 美元。公司内部人士持有 20.90% 的公司股票。</p>
<h2>机构投资者对阿尔法泰克的看法</h2>
<p>一些对冲基金最近买入和卖出了该公司的股票。先锋集团在第三季度将其在阿尔法泰克的持股增加了 2.4%。先锋集团目前持有 6,815,058 股医疗技术公司的股票，价值为 99,091,000 美元，此前在上个季度又购买了 158,295 股。Tudor Investment Corp ET AL 在第三季度将其在阿尔法泰克的持股增加了 608.4%。Tudor Investment Corp ET AL 目前持有 900,491 股医疗技术公司的股票，价值为 13,093,000 美元，此前在上个季度又购买了 773,367 股。Lisanti Capital Growth LLC 在第三季度获得了阿尔法泰克的新持股，价值约为 3,305,000 美元。阿伯丁集团在第四季度将其在阿尔法泰克的持股增加了 29.7%。阿伯丁集团目前持有 1,286,195 股医疗技术公司的股票，价值为 27,062,000 美元，此前在上个季度又购买了 294,792 股。最后，SG Americas Securities LLC 在第三季度获得了阿尔法泰克的新持股，价值约为 1,115,000 美元。目前 66.35% 的股票由机构投资者持有。</p>
<h2>阿尔法泰克的关键新闻</h2>
<p>以下是本周影响阿尔法泰克的关键新闻故事：</p>
<ul>
<li>积极情绪：HC Wainwright 重申了 &#34;买入&#34; 评级，并设定了 24.00 美元的目标价，表明分析师对该股的看涨信心以及与当前水平相比的巨大上行空间。文章标题</li>
<li>积极情绪：Alphatec 报告第一季度案例量增长 21%，这是投资者重视的运营指标，表明脊柱手术的持久需求。强劲的案例量有助于支持收入势头。Alphatec 第一季度案例量增长 21%</li>
<li>积极情绪：Alphatec 宣布了一项新的联合高级担保信贷设施，改善了增长计划的流动性并降低了再融资风险。这通常会让投资者对短期融资感到安心。Alphatec 为增长建立新的联合信贷设施</li>
<li>中性情绪：摩根大通维持了超配/买入立场（报告为买入），但将目标价下调至 16 美元——这是一个混合信号：持续的机构支持但估值基准降低。Alphatec NASDAQ: ATEC 目标价在摩根大通下调至 16.00 美元</li>
<li>消极情绪：Needham &amp; Company 将目标价从 25 美元下调至 14 美元（尽管仍维持 &#34;买入&#34;），反映出短期预期降低，并对情绪施加下行压力。Alphatec NASDAQ: ATEC 目标价在 Needham &amp; Company LLC 下调至 14.00 美元</li>
<li>消极情绪：TD Cowen 将目标价大幅下调至 11 美元（从 20 美元），尽管保持 &#34;买入&#34;，其他公司（Needham、摩根大通）也下调了目标——分析师的降级/下调对估值造成压力。文章标题</li>
<li>消极情绪：在管理层下调全年收入展望后，股价曾大幅下跌，这一重大负面消息增加了波动性，并可能促使近期分析师的修正。Alphatec 股价在全年收入展望下调后暴跌</li>
<li>消极情绪：两家律师事务所（Ademi LLP 和 Johnson Fistel）宣布对 Alphatec 进行潜在证券索赔的调查，增加了法律风险和投资者的不确定性。股东警报 Johnson Fistel 发布</li>
<li>消极情绪：披露一只基金在上个季度出售了约 1800 万美元的 ATEC 股票，增加了卖压背景，并可能表明投资者在收益和指引变动后进行风险降低。该基金披露出售了 1800 万美元的 Alphatec 股票</li>
</ul>
<h2>关于 Alphatec</h2>
<p>(获取免费报告)</p>
<p>Alphatec Holdings, Inc NASDAQ: ATEC 是一家医疗技术公司，专注于用于外科矫正退行性脊柱疾病的产品的设计、开发和商业化。公司的产品组合以体间植入物、生物材料、固定装置和外科规划工具为中心，旨在改善脊柱融合手术中的患者结果。Alphatec 的旗舰产品包括可定制的体间笼、骨移植材料和专门的仪器，旨在用于微创和开放脊柱手术。</p>
<p>公司成立于 1985 年，最初名为 Alphatec Spine，并于 2018 年更名为 Alphatec Holdings，已从单一产品组织发展为脊柱市场的多平台创新者。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过 Alphatec</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVRFQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVRFQw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Alphatec 吗？</h2>
<p>在你考虑 Alphatec 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛市场注意到之前立即购买……而 Alphatec 并不在名单上。</p>
<p>虽然 Alphatec 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

阿尔法泰克控股

标普健康医疗设备 ETF - SPDR

美国医药设备 ETF - iShares

<p>富国银行（Wells Fargo & Company）已将阿尔法泰克控股（Alphatec，NASDAQ: ATEC）的目标股价从 28.00 美元下调至 14.00 美元，同时维持 “增持” 评级。这表明与前一交易日收盘价相比，仍有 83.37% 的上涨潜力。其他分析师也调整了他们的评级，加拿大投资公司（Canaccord Genuity）设定的目标为 23.00 美元，HC Wainwright 则为 24.00 美元。阿尔法泰克控股的股票最近交易价格为 7.64 美元，市值为 11.7 亿美元。该公司在上个季度报告的收入为 1.9211 亿美元，未能达到预期</p>

<p>Alphatec (NASDAQ:ATEC - Get Free Report) had its price objective decreased by investment analysts at Wells Fargo &amp; Company from $28.00 to $14.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has an &#34;overweight&#34; rating on the medical technology company's stock. Wells Fargo &amp; Company's price objective would suggest a potential upside of 83.37% from the company's previous close.</p>
<div class="lb-trans"><p>阿尔法泰克（NASDAQ:ATEC - 获取免费报告）在周四发布给客户和投资者的研究报告中，投资分析师将其目标价格从 28.00 美元下调至 14.00 美元，彭博社报道。该公司目前对这家医疗技术公司的股票给予 “增持” 评级。摩根士丹利的目标价格暗示该公司股价有 83.37% 的潜在上涨空间。</p>
</div><p>Several other equities analysts also recently issued reports on the company. Canaccord Genuity Group reduced their price objective on Alphatec from $25.00 to $23.00 and set a &#34;buy&#34; rating for the company in a research report on Wednesday. HC Wainwright reissued a &#34;buy&#34; rating and set a $24.00 target price on shares of Alphatec in a research note on Thursday. Weiss Ratings reissued a &#34;sell (e+)&#34; rating on shares of Alphatec in a research note on Friday, March 27th. Wall Street Zen raised shares of Alphatec from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, January 31st. Finally, Barclays reissued an &#34;overweight&#34; rating and set a $24.00 target price (down from $27.00) on shares of Alphatec in a research note on Thursday. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $18.58.</p>
<div class="lb-trans"><p>其他几位股票分析师最近也对该公司发布了报告。Canaccord Genuity Group 将阿尔法泰克的目标价格从 25.00 美元下调至 23.00 美元，并在周三的研究报告中给予该公司 “买入” 评级。HC Wainwright 在周四的研究报告中重申了 “买入” 评级，并设定了 24.00 美元的目标价格。Weiss Ratings 在 3 月 27 日的研究报告中重申了阿尔法泰克的 “卖出（e+）” 评级。Wall Street Zen 在 1 月 31 日的研究报告中将阿尔法泰克的评级从 “持有” 上调至 “买入”。最后，巴克莱在周四的研究报告中重申了 “增持” 评级，并将目标价格设定为 24.00 美元（低于 27.00 美元）。十位投资分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，平均目标价格为 18.58 美元。</p>
</div><p><strong>Check Out Our Latest Report on ATEC</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 ATEC 的最新报告</strong></p>
</div><h2>Alphatec Stock Up 9.2%</h2>
<div class="lb-trans"><h2>阿尔法泰克股票上涨 9.2%</h2>
</div><p>NASDAQ:ATEC traded up $0.65 during mid-day trading on Thursday, hitting $7.64. The company had a trading volume of 5,070,841 shares, compared to its average volume of 3,239,526. The business has a fifty day simple moving average of $11.60 and a 200-day simple moving average of $15.90. The company has a current ratio of 2.06, a quick ratio of 1.28 and a debt-to-equity ratio of 40.35. Alphatec has a 1 year low of $6.85 and a 1 year high of $23.29. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of -9.34 and a beta of 0.96.</p>
<div class="lb-trans"><p>在周四的午盘交易中，NASDAQ:ATEC 上涨 0.65 美元，达到 7.64 美元。该公司的交易量为 5,070,841 股，而其平均交易量为 3,239,526 股。该公司的 50 日简单移动平均为 11.60 美元，200 日简单移动平均为 15.90 美元。公司的流动比率为 2.06，速动比率为 1.28，债务与股本比率为 40.35。阿尔法泰克的 1 年最低价为 6.85 美元，1 年最高价为 23.29 美元。该公司的市值为 11.7 亿美元，市盈率为-9.34，贝塔值为 0.96。</p>
</div><p>Alphatec (NASDAQ:ATEC - Get Free Report) last announced its earnings results on Tuesday, May 5th. The medical technology company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.21). Alphatec had a negative return on equity of 788.36% and a negative net margin of 15.93%.The business had revenue of $192.11 million for the quarter, compared to analysts' expectations of $197.51 million. During the same period in the previous year, the firm posted ($0.35) earnings per share. The firm's revenue was up 13.6% compared to the same quarter last year. Equities analysts forecast that Alphatec will post -0.28 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>阿尔法泰克（NASDAQ:ATEC - 获取免费报告）最后一次公布财报是在 5 月 5 日，医疗技术公司报告每股收益（EPS）为-0.22 美元，低于分析师一致预期的-0.01 美元，差距为-0.21 美元。阿尔法泰克的股本回报率为-788.36%，净利润率为-15.93%。该公司在本季度的收入为 1.9211 亿美元，而分析师预期为 1.9751 亿美元。在去年同期，该公司每股收益为-0.35 美元。与去年同期相比，该公司的收入增长了 13.6%。股票分析师预测阿尔法泰克在本财年的每股收益将为-0.28 美元。</p>
</div><h2>Insider Buying and Selling at Alphatec</h2>
<div class="lb-trans"><h2>阿尔法泰克的内部买卖</h2>
</div><p>In related news, COO Scott Lish sold 260,535 shares of the company's stock in a transaction on Friday, March 13th. The shares were sold at an average price of $12.30, for a total value of $3,204,580.50. Following the completion of the sale, the chief operating officer directly owned 815,704 shares in the company, valued at approximately $10,033,159.20. This represents a 24.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, General Counsel Tyson Eliot Marshall sold 88,835 shares of the company's stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $12.49, for a total transaction of $1,109,549.15. Following the completion of the sale, the general counsel owned 559,459 shares of the company's stock, valued at $6,987,642.91. This represents a 13.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 629,189 shares of company stock valued at $7,801,589. Company insiders own 20.90% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席运营官 Scott Lish 在 3 月 13 日的交易中出售了 260,535 股公司的股票。股票以平均价格 12.30 美元出售，总价值为 3,204,580.50 美元。出售完成后，首席运营官直接持有该公司 815,704 股股票，价值约为 10,033,159.20 美元。这代表其持股比例减少了 24.21%。该交易在向 SEC 提交的文件中披露，文件可通过此链接访问。此外，法律顾问 Tyson Eliot Marshall 在 3 月 5 日的交易中出售了 88,835 股公司的股票。股票以平均价格 12.49 美元出售，总交易额为 1,109,549.15 美元。出售完成后，法律顾问持有 559,459 股公司的股票，价值为 6,987,642.91 美元。这代表其持股比例减少了 13.70%。该交易的披露信息可在 SEC 文件中找到。在过去三个月中，内部人士共出售了 629,189 股公司股票，价值为 7,801,589 美元。公司内部人士持有 20.90% 的公司股票。</p>
</div><h2>Institutional Investors Weigh In On Alphatec</h2>
<div class="lb-trans"><h2>机构投资者对阿尔法泰克的看法</h2>
</div><p>A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Alphatec by 2.4% during the third quarter. Vanguard Group Inc. now owns 6,815,058 shares of the medical technology company's stock valued at $99,091,000 after buying an additional 158,295 shares during the last quarter. Tudor Investment Corp ET AL raised its position in Alphatec by 608.4% in the third quarter. Tudor Investment Corp ET AL now owns 900,491 shares of the medical technology company's stock worth $13,093,000 after purchasing an additional 773,367 shares in the last quarter. Lisanti Capital Growth LLC acquired a new position in Alphatec in the third quarter worth about $3,305,000. Aberdeen Group plc raised its position in Alphatec by 29.7% in the fourth quarter. Aberdeen Group plc now owns 1,286,195 shares of the medical technology company's stock worth $27,062,000 after purchasing an additional 294,792 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in Alphatec in the third quarter worth about $1,115,000. 66.35% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些对冲基金最近买入和卖出了该公司的股票。先锋集团在第三季度将其在阿尔法泰克的持股增加了 2.4%。先锋集团目前持有 6,815,058 股医疗技术公司的股票，价值为 99,091,000 美元，此前在上个季度又购买了 158,295 股。Tudor Investment Corp ET AL 在第三季度将其在阿尔法泰克的持股增加了 608.4%。Tudor Investment Corp ET AL 目前持有 900,491 股医疗技术公司的股票，价值为 13,093,000 美元，此前在上个季度又购买了 773,367 股。Lisanti Capital Growth LLC 在第三季度获得了阿尔法泰克的新持股，价值约为 3,305,000 美元。阿伯丁集团在第四季度将其在阿尔法泰克的持股增加了 29.7%。阿伯丁集团目前持有 1,286,195 股医疗技术公司的股票，价值为 27,062,000 美元，此前在上个季度又购买了 294,792 股。最后，SG Americas Securities LLC 在第三季度获得了阿尔法泰克的新持股，价值约为 1,115,000 美元。目前 66.35% 的股票由机构投资者持有。</p>
</div><h2>Key Alphatec News</h2>
<div class="lb-trans"><h2>阿尔法泰克的关键新闻</h2>
</div><p>Here are the key news stories impacting Alphatec this week:</p>
<div class="lb-trans"><p>以下是本周影响阿尔法泰克的关键新闻故事：</p>
</div><ul>
<li>Positive Sentiment: HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $24.00 price target, signaling bullish analyst conviction and a large upside vs current levels. Article Title</li>
<li>Positive Sentiment: Alphatec reported 21% case-volume growth in Q1, an operational metric investors prize for durable demand in spine procedures. Strong volume helps support revenue momentum. Alphatec sees 21% case volume growth in Q1</li>
<li>Positive Sentiment: Alphatec announced a new syndicated senior secured credit facility, improving liquidity for growth initiatives and reducing refinancing risk. That typically reassures investors about near-term funding. Alphatec Establishes New Syndicated Credit Facility for Growth</li>
<li>Neutral Sentiment: J.P. Morgan/Chase maintained an overweight/buy stance (reported as a buy), but lowered its price target to $16 — a mixed signal: continued institutional support but a reduced valuation anchor. Alphatec NASDAQ: ATEC Price Target Lowered to $16.00 at JPMorgan Chase &amp; Co.</li>
<li>Negative Sentiment: Needham &amp; Company cut its price target from $25 to $14 (though it remains a &#34;buy&#34;), reflecting reduced near-term expectations and putting downward pressure on sentiment. Alphatec NASDAQ: ATEC Price Target Lowered to $14.00 at Needham &amp; Company LLC</li>
<li>Negative Sentiment: TD Cowen cut its price target sharply to $11 (from $20) despite keeping a &#34;buy,&#34; and other firms (Needham, JPMorgan) trimmed targets — analyst downgrades/cuts are weighing on valuation. Article Title</li>
<li>Negative Sentiment: Shares previously plunged after management cut the full‑year revenue outlook, a material negative that increased volatility and likely prompted recent analyst revisions. Alphatec Shares Plummet After Full-Year Revenue Outlook Is Cut</li>
<li>Negative Sentiment: Two law firms (Ademi LLP and Johnson Fistel) announced investigations into potential securities claims against Alphatec, heightening legal risk and investor uncertainty. Shareholder AlertJohnson Fistel Release</li>
<li>Negative Sentiment: Disclosure that a fund sold ~$18M of ATEC shares last quarter adds selling pressure context and may signal investor de-risking after the earnings and guidance moves. This Fund Disclosed Selling $18 Million in Alphatec</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：HC Wainwright 重申了 &#34;买入&#34; 评级，并设定了 24.00 美元的目标价，表明分析师对该股的看涨信心以及与当前水平相比的巨大上行空间。文章标题</li>
<li>积极情绪：Alphatec 报告第一季度案例量增长 21%，这是投资者重视的运营指标，表明脊柱手术的持久需求。强劲的案例量有助于支持收入势头。Alphatec 第一季度案例量增长 21%</li>
<li>积极情绪：Alphatec 宣布了一项新的联合高级担保信贷设施，改善了增长计划的流动性并降低了再融资风险。这通常会让投资者对短期融资感到安心。Alphatec 为增长建立新的联合信贷设施</li>
<li>中性情绪：摩根大通维持了超配/买入立场（报告为买入），但将目标价下调至 16 美元——这是一个混合信号：持续的机构支持但估值基准降低。Alphatec NASDAQ: ATEC 目标价在摩根大通下调至 16.00 美元</li>
<li>消极情绪：Needham &amp; Company 将目标价从 25 美元下调至 14 美元（尽管仍维持 &#34;买入&#34;），反映出短期预期降低，并对情绪施加下行压力。Alphatec NASDAQ: ATEC 目标价在 Needham &amp; Company LLC 下调至 14.00 美元</li>
<li>消极情绪：TD Cowen 将目标价大幅下调至 11 美元（从 20 美元），尽管保持 &#34;买入&#34;，其他公司（Needham、摩根大通）也下调了目标——分析师的降级/下调对估值造成压力。文章标题</li>
<li>消极情绪：在管理层下调全年收入展望后，股价曾大幅下跌，这一重大负面消息增加了波动性，并可能促使近期分析师的修正。Alphatec 股价在全年收入展望下调后暴跌</li>
<li>消极情绪：两家律师事务所（Ademi LLP 和 Johnson Fistel）宣布对 Alphatec 进行潜在证券索赔的调查，增加了法律风险和投资者的不确定性。股东警报 Johnson Fistel 发布</li>
<li>消极情绪：披露一只基金在上个季度出售了约 1800 万美元的 ATEC 股票，增加了卖压背景，并可能表明投资者在收益和指引变动后进行风险降低。该基金披露出售了 1800 万美元的 Alphatec 股票</li>
</ul>
</div><h2>About Alphatec</h2>
<div class="lb-trans"><h2>关于 Alphatec</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Alphatec Holdings, Inc NASDAQ: ATEC is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company's portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec's flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.</p>
<div class="lb-trans"><p>Alphatec Holdings, Inc NASDAQ: ATEC 是一家医疗技术公司，专注于用于外科矫正退行性脊柱疾病的产品的设计、开发和商业化。公司的产品组合以体间植入物、生物材料、固定装置和外科规划工具为中心，旨在改善脊柱融合手术中的患者结果。Alphatec 的旗舰产品包括可定制的体间笼、骨移植材料和专门的仪器，旨在用于微创和开放脊柱手术。</p>
</div><p>Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.</p>
<div class="lb-trans"><p>公司成立于 1985 年，最初名为 Alphatec Spine，并于 2018 年更名为 Alphatec Holdings，已从单一产品组织发展为脊柱市场的多平台创新者。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Alphatec</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Alphatec</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVRFQw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=ATEC"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Alphatec Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Alphatec 吗？</h2>
</div><p>Before you consider Alphatec, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Alphatec 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alphatec wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛市场注意到之前立即购买……而 Alphatec 并不在名单上。</p>
</div><p>While Alphatec currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Alphatec 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Alphatec (NASDAQ:ATEC) Given New $14.00 Price Target at Wells Fargo & Company

Market Beat

富国银行

巴克莱银行

Lisata Therapeutics

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

阿尔法泰克控股（NASDAQ:ATEC）被富国银行给予新的 14.00 美元目标价